UNH Stock Gets Cheaper Only If The Margins Come Back
Consensus knocks a quarter off the health insurer’s earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.
UnitedHealth (UNH) trades near $393 after returning about 33% over the past year. On the last twelve months of adjusted earnings that is a price-to-earnings ratio of about 23.4. Analysts have it much cheaper by 2027, for reasons almost unrelated to covering more people.
Consensus For 2026 Is Just The Company’s Own Guide
The multiple is about 19.8 times on the earnings analysts expect for 2026, and about 17.5 times on what they expect for 2027. That step down from 23.4 is real margin recovery, not an accounting illusion: the trailing figure already adds back stock-based compensation to align with consensus, narrowing the measurement gap rather than creating it. The near leg is barely a forecast. Management raised its 2026 adjusted earnings per share guidance to $19.50 to $20, and consensus for 2026 sits at about $19.76, inside that band. The bet is 2027, where 19 analysts range from $21.11 to $23.90 a share.
Margin, Not Members, Does All The Work
Consensus has earnings expanding by roughly a third overall from the trailing twelve months to 2027 while revenue grows about 1.3% a year. That is a margin forecast wearing a growth forecast’s clothes. On about $450 billion of trailing revenue, the operating margin over the last twelve months was 4.8% against a three-year average of 7.1%, so the room exists and consensus assumes it gets used. Betting on margin repair of that scale is a different proposition from the Trefis High Quality Portfolio, which screens for businesses whose margins are already strong.
The flat revenue line is deliberate: management has been trading membership for margin, with full-year Medicare Advantage enrollment set to decline by approximately 1.1 million and the individual ACA business contracting. Revenue grew 6.5% over the last twelve months but only 0.4% in the most recent quarter.
Commercial Is The Piece That Slipped Past 2027
The repair is real in places: Medicare margins should finish 2026 above 3%, and the Optum Health outlook was raised too. But commercial medical cost trends are running modestly above 11%, pushed partly by arbitration disputes under the No Surprises Act. Management frames the extended commercial recovery as a timing delay rather than a structural setback, but for investors, timing is the entire problem: 2027 is the exact year the low forward multiple depends on, and commercial sits inside UnitedHealthcare, which accounts for about $12 billion of the group’s roughly $25.45 billion in guided 2026 operating earnings.
Seven Percent Up Only If The Market Pays A Higher Multiple
If the share price never moves, the stock ends up at about 17.5 times its 2027 earnings, which would show today’s price was not an overpayment, but would not pay you anything. Settle the multiple at about 18.7 times the 2027 figure, halfway between the two forward years, and the stock would be worth about $419, roughly 7% above today’s price. The stock has returned 3.9% over the past three months and sits about 10% below its 52-week high. In past market shocks, the 2008-2009 global financial crisis and the 2025 US tariff shock among them, it has fallen as much as 72% from peak to trough. So the earnings have to arrive on schedule for even a modest gain, and whether the guidance keeps climbing is what tells you they will.
What A Stock Is Worth And How Much To Own Are Different Questions
Valuation says what a stock might be worth, it says nothing about how much of your wealth should ride on it. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.